New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Intrommune Therapeutics is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Nelson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Intrommune Therapeutics
Intrommune is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy. Intrommunes core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and stabilize allergenic proteins, representing a new therapeutic approach for the treatment of peanut and other food allergies. Conducting allergy immunotherapy via teeth brushing is referred to as oral mucosal immunotherapy (OMIT). OMIT delivers allergenic proteins to the areas of the oral cavity, potentially driving the immune system toward tolerance without ingestion of the allergen. OMIT may address a significant health care need in the industrialized world, where the spread of food allergies has been characterized as an epidemic. Intrommunes mission is to develop safe and effective options for food allergy sufferers so they and their loved ones can live their lives without fear.

To learn more about Intrommune Therapeutics, visit http://intrommune.com/

Contact:
Michael Nelson, Chief Executive Officer
646-770-2533
mnelson@intrommune.com
https://www.linkedin.com/in/michael-nelson-ceo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved